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Résumé en
anglais
Antimicrobial peptides, also known as host defense peptides, have recently emerged
as a promising new category of therapeutic agents for the treatment of infectious
diseases. This study evaluated the preclinical , and antimicrobial activity, as well as
the potential to cause skin irritation, of human kininogen-derived antimicrobial
peptide DPK-060 in different formulations designed for topical delivery. We found
that DPK-060 formulated in acetate buffer or poloxamer gel caused a marked
reduction of bacterial counts of (minimum microbicidal concentration <5 μg/ml). We
also found that DPK-060 in poloxamer gel significantly suppressed microbial survival
in an wound infection model using pig skin and in an mouse model of surgical site
infection (≥99 or ≥94% reduction in bacterial counts was achieved with 1% DPK-060
at 4 h post-treatment, respectively). Encapsulation of DPK-060 in different types of
lipid nanocapsules or cubosomes did not improve the bactericidal potential of the
peptide under the applied test conditions. No reduction in cell viability was observed
in response to administration of DPK-060 in any of the formulations tested. In
conclusion, the present study confirms that DPK-060 has the potential to be an
effective and safe drug candidate for the topical treatment of microbial infections;
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